To save researchers time and resources, The Michael J. Fox Foundation has made a number of tools available to the scientific community at low cost, with rapid delivery.
Helpful Resources
-
Sponsored Tools Program
Learn more about how MJFF can help share your tools.
-
Tools Consortium
MJFF is working with industry to develop priority tools.
-
Preclinical Models
Learn more about the various in vivo models used in Parkinson's disease research.
Find a Research Tool
Filter by Tool Type or Gene/Protein Type to Organize Results
* = MJFF does not control pricing or terms of availability for this tool.
Filters
SPTSSB Knockout MCF-7 Cell Line
Immortalized Cell
MCF-7 cell line with homozygous knockout of SPTSSB. This cell line development project is part of the Aligning Science Across Parkinson’s (ASAP) Initiative. Anticipated Availability: Q4 2026
Usp30 Knockout RAW264.7 Cell Line
Immortalized Cell
RAW264.7 cell line with homozygous knockout of Usp30. This cell line development project is part of the MJFF Targets to Therapies (T2T) Initiative. Anticipated Availability: Q4 2026
CLN3 Edited iPSC Lines
Human iPS Cell
KOLF2.1J human iPSC line with CRISPR-engineered mutations in CLN3, including heterozygous and homozygous R334H, heterozygous and homozygous V330I, and homozygous knockout mutations. These lines were generated within the iPSC Neurodegeneration Initiative for Parkinson’s Disease (iNDI-PD) which is supported by the Aligning Science Across Parkinson’s (ASAP) Initiative. Estimated Availability: Late 2025
PINK1 Edited iPSC Lines
Human iPS Cell
KOLF2.1J human iPSC line with CRISPR-engineered mutations in PINK1, including:- -A217D (heterozygous and homozygous)
- -M313I (heterozygous and homozygous) - in development, est late 2025
- -L347P (heterozygous and homozygous) - in development, est late 2025
- -P399L (heterozygous and homozygous)
GALC Knockout AGS Cell Line
Immortalized Cell
AGS cell with homozygous knockout of GALC. Estimated Availability: Late 2026
PPM1M Knockout A-375 Cell Line
Immortalized Cell
A-375 cell line with homozygous knockout of PPM1M. Anticipated Availability: Q4 2026
Rab21 Knockout A-375 Cell Line
Immortalized Cell
A-375 cell line with homozygous knockout of Rab21. Anticipated Availability: Q4 2026
ITSN1 Edited iPSC Lines
Human iPS Cell
KOLF2.1J human iPSC line with CRISPR-engineered mutations in ITSN1, including:- - R992* (heterozygous and homozygous)
- - Knockout (homozygous)
GBA1LP Edited iPSC Lines
Human iPS Cell
KOLF2.1J human iPSC line with CRISPR-engineered homozygous knockout of GBA1LP. These lines were generated within the iPSC Neurodegeneration Initiative for Parkinson’s Disease (iNDI-PD) which is supported by the Aligning Science Across Parkinson’s (ASAP) Initiative. Estimated Availability: Late 2025
GPNMB Edited iPSC Lines
Human iPS Cell
KOLF2.1J human iPSC line with CRISPR-engineered mutations in GPNMB, including heterozygous and homozygous knockout. These lines were generated within the iPSC Neurodegeneration Initiative for Parkinson’s Disease (iNDI-PD) which is supported by the Aligning Science Across Parkinson’s (ASAP) Initiative. Estimated Availability: Late 2025
Have questions or need additional information?
Email tools@michaeljfox.org with questions and to suggest new tools for us to develop. Or visit our FAQ page.
"We have shown, thanks in part to MJFF, that researchers now have in their pantry the right ‘ingredients’, to... help to drive forward PD drug development.”
Heather Melrose, PhD
Mayo Clinic